# Janux Therapeutics, Inc.: Form 8-K, filed Jan 22, 2026

- Company: [Janux Therapeutics, Inc.](/companies/janx.md) (CIK 1817713)
- Form: 8-K
- Filed: 2026-01-22
- Accepted by EDGAR: Jan 22, 2026, 16:30 ET
- Period: 2026-01-21
- Accession: 0001193125-26-019520
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1817713/000119312526019520/janx-20260121.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1817713/000119312526019520/

## Items reported

- Item 1.01: Entry into a material agreement
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1817713/000119312526019520/janx-20260121.htm

Filed Jan 22, 2026.
Source: SEC EDGAR, the filing index for accession 0001193125-26-019520. Last ingested by Listed: Nov 5, 2026, 18:20 ET. No prices; not investment advice.